[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100588675":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":20,"locations":26,"responsibleParty":74,"collaborators":10,"id":78,"slug":79,"hasResults":80,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":80,"sex":86,"minAge":87,"maxAge":10,"enrollmentInfo":88,"targetDuration":91,"studyType":92,"phases":10,"briefSummary":93,"conditions":94,"keywords":10,"overallStatus":29,"whyStopped":10,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":105},{"fullName":5,"class":6},"Seoul National University Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"same-day group",null,"planning angiography, MAA scan, and radioembolization was performed in a single day",[13],"Procedure: same-day radioembolization",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"PROCEDURE","same-day radioembolization","On the day of the procedure, angiography is performed, followed by cone-beam CT of the hepatic artery. After injecting 99mTc-MAA into the hepatic artery, the patient is transferred to the nuclear medicine department for a lung shunt scan and lung SPECT\u002FCT. The lung shunt fraction is determined using the planar images.\n\nUsing diagnostic CT\u002FMRI and 99mTc-MAA images, the treatment dose is calculated with the multi-compartment MIRD method. The acceptable range for tumor absorbed dose is ≥100 Gy, and the lung dose must be ≤15 Gy. The tumor absorbed dose must be at least 100 Gy and should ideally be within the range of 300 to 600 Gy. There is no upper limit for the tumor absorbed dose.",[9],[21],{"name":22,"role":23,"phone":24,"phoneExt":10,"email":25},"Hyo-Cheol Kim, MD","CONTACT","82-10-5136-5205","radioembolization@snu.ac.kr",[27,43,57,64],{"facility":28,"status":29,"city":30,"state":10,"zip":10,"country":31,"countryCode":10,"cosmosGeoPoint":32,"geoPoint":37,"contacts":38},"National Cancer Center","RECRUITING","Goyang","South Korea",{"type":33,"coordinates":34},"Point",[35,36],127.19731,36.21689,{"lat":36,"lon":35},[39],{"name":40,"role":23,"phone":41,"phoneExt":10,"email":42},"In Joon Lee","82-10-6429-2012","2injoon@hanmail.net",{"facility":44,"status":45,"city":46,"state":10,"zip":10,"country":31,"countryCode":10,"cosmosGeoPoint":47,"geoPoint":51,"contacts":52},"Samsung Medical Center","NOT_YET_RECRUITING","Seoul",{"type":33,"coordinates":48},[49,50],126.9784,37.566,{"lat":50,"lon":49},[53],{"name":54,"role":23,"phone":55,"phoneExt":10,"email":56},"Dong Ho Hyun","82-10-8809-6722","mesentery@naver.com",{"facility":5,"status":29,"city":46,"state":10,"zip":10,"country":31,"countryCode":10,"cosmosGeoPoint":58,"geoPoint":60,"contacts":61},{"type":33,"coordinates":59},[49,50],{"lat":50,"lon":49},[62],{"name":22,"role":23,"phone":63,"phoneExt":10,"email":25},"82-2-2072-0760",{"facility":65,"status":45,"city":46,"state":10,"zip":10,"country":31,"countryCode":10,"cosmosGeoPoint":66,"geoPoint":68,"contacts":69},"Severance hospital",{"type":33,"coordinates":67},[49,50],{"lat":50,"lon":49},[70],{"name":71,"role":23,"phone":72,"phoneExt":10,"email":73},"Gyoung Min Kim","821042430703","gyoungmin@gmail.com",{"type":75,"investigatorFullName":76,"investigatorTitle":77,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Hyo-Cheol Kim","Professor","100588675","same-day-radioembolization-for-large-hcc-100588675",false,"NCT06944483","Same-day Radioembolization for Large HCC","Same-day Radioembolization for Large HCC (>5cm) With Y90 Resin Microspheres : Multicenter Prospective Registry Study","ISTAR-01","Inclusion Criteria:\n\n* Patients diagnosed with hepatocellular carcinoma histologically and\u002For radiologically (LI-RADS 4 or 5)\n* hepatocellular carcinoma 5cm or larger\n* dysmorphic intratumoral vessels 3mm or smaller\n* Child-Pugh class A\n* ECOG 0 or 1\n* the following lab should be met. A. Leukocytes ≥ 1,000\u002FµL and ≤ 20,000\u002FµL B. Hemoglobin ≥ 6.0 g\u002FdL (transfusion allowed to meet this criterion) C. Total bilirubin ≤ 2.0 mg\u002FdL D. Platelet ≥ 40,000\u002FµL E. International normalized ratio (INR) ≤ 2.0 for patients not taking anticoagulants F. Aspartate transaminase (AST) ≤ 800 IU\u002FL (i.e., ≤ 20X upper normal limit) G. Alanine transaminase (ALT) ≤ 800 IU\u002FL (i.e., ≤ 20X upper normal limit) H. Creatinine ≤ 2.5 mg\u002FdL (if patient is receiving hemodialysis, no upper limit of creatinine)\n* Patients with a life expectancy of \\>3 mo\n* Patients who have adequately understood the clinical trial and consented in writing\n* Nonpregnant women of childbearing potential\n\nExclusion Criteria:\n\n* hepatic vein invasion on CT\u002FMRI\n* Marked enhancement of portal vein or hepatic vein on arterial phase of CT\u002FMRII\n* TIPS\n* dysmorphic intratumoral vessels \\> 3mm\n* main portal vein invasion\n* significant COPD or interstitial lung disease\n* biliary stent or enterobiliary anastomosis","ALL","19 Years",{"count":89,"type":90},138,"ESTIMATED","12 Months","OBSERVATIONAL","In patients who has no sign suggesting high lung shunt fraction (TIPS, hepatic vein invasion, hepatic vein enhancement on arterial phase, dysmorphic intratumoral vessel), planning angiography, MAA scan, and radioembolization are performed in a single day with SIR-Spheres. This prospective registry will prove that the selection criteria is accurate and same-day radioembolization is feasible and safe.",[95],"Hepatocellular Carcinoma (HCC)","2026-08-16",{"date":98,"type":99},"2026-08-18","ACTUAL",{"date":101,"type":99},"2025-04-25",{"date":103,"type":90},"2029-12-31",{"name":5,"class":6},4]